Literature DB >> 9686939

Investigation of the subtypes of alpha2-adrenoceptor mediating prejunctional inhibition in rat atrium and cerebral cortex.

S L Ho1, V Honner, J R Docherty.   

Abstract

We have investigated the subtype of alpha2-adrenoceptor mediating prejunctional inhibition of neurotransmission in rat atrium in comparison with the alpha2-adrenoceptor mediating prejunctional inhibition in rat cerebral cortex. In rat atrium and cerebral cortex, prejunctional alpha2-adrenoceptors were investigated in terms of the ability of alpha2-adrenoceptor antagonists to increase the stimulation-evoked overflow of tritium in tissues pre-incubated with [3H]-noradrenaline. The relatively non-selective alpha2-adrenoceptor antagonist yohimbine and the alpha2D-adrenoceptor selective antagonist BRL 44408 had potencies in rat atrium which were similar to their potencies in rat cerebral cortex. The antagonists ARC 239, HV 723, WB 4101, prazosin, chlorpromazine and abanoquil, which have low affinity for alpha2D-adrenoceptors, significantly increased stimulation-evoked overflow at lower concentrations in rat atrium than rat cerebral cortex. Antagonist potency at prejunctional alpha2-adrenoceptors was correlated with antagonist affinity at alpha2-adrenoceptor ligand binding sites in membranes of rat kidney (alpha2B) and submandibular gland (alpha2D), and human recombinant alpha2C-adrenoceptors labelled with [3H]yohimbine. The correlation between ligand binding sites and the functional receptor in the rat cerebral cortex was significant only for the alpha2D-adrenoceptor ligand binding site (r=0.87, n=8, P<0.01) as compared to the alpha2B-adrenoceptor (r=0.32, n.s.) or alpha2C-adrenoceptor (r=0.12, n.s.) ligand binding sites. The correlation between ligand binding sites and the functional receptor in the rat atrium was not significant for any ligand binding site, with r=0.64, 0.68 and 0.67 for the alpha2D-, the alpha2B- and the alpha2C-adrenoceptor ligand binding sites, respectively. It is concluded that the functional prejunctional alpha2-adrenoceptor of rat cerebral cortex closely resembles the alpha2D-adrenoceptor ligand binding site of rat submandibular gland, but the rat atrium may contain two subypes of prejunctional alpha2-adrenoceptor, alpha2D and another subtype, possibly alpha2B or alpha2C.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9686939     DOI: 10.1007/pl00005218

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  7 in total

1.  Investigation of neurotransmission in vas deferens from alpha(2A/D)-adrenoceptor knockout mice.

Authors:  Linda Cleary; Catherine Vandeputte; James R Docherty
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

2.  Investigation of postjunctional alpha1- and alpha2-adrenoceptor subtypes in vas deferens from wild-type and alpha(2A/D)-adrenoceptor knockout mice.

Authors:  Linda Cleary; Catherine Vandeputte; James R Docherty
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

Review 3.  The role of monoamines in the changes in body temperature induced by 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its derivatives.

Authors:  J R Docherty; A R Green
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

4.  Role of alpha2A-adrenoceptors in the effects of MDMA on body temperature in the mouse.

Authors:  Sotiria Bexis; James R Docherty
Journal:  Br J Pharmacol       Date:  2005-09       Impact factor: 8.739

5.  Use of knockout technology to resolve pharmacological problems.

Authors:  J R Docherty
Journal:  Br J Pharmacol       Date:  2006-11-13       Impact factor: 8.739

6.  Modulation of nicotine-induced attentional enhancement in rats by adrenoceptor antagonists.

Authors:  Britta Hahn; Ian P Stolerman
Journal:  Psychopharmacology (Berl)       Date:  2004-07-14       Impact factor: 4.530

7.  Role of alpha1-adrenoceptor subtypes in the effects of methylenedioxy methamphetamine (MDMA) on body temperature in the mouse.

Authors:  S Bexis; J R Docherty
Journal:  Br J Pharmacol       Date:  2007-11-26       Impact factor: 8.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.